TROP2 Targeting Delays Resistance to Lung Cancer Therapy in Preclinical Models
A new strategy combining a TROP2-targeting drug with osimertinib may delay the inevitable resistance that undermines EGFR-mutant lung cancer treatment.
Summary
One of the biggest challenges in treating EGFR-mutant lung cancer is that tumors eventually develop resistance to targeted therapies. This study identifies a population of 'drug-tolerant persister' cells that survive initial treatment and seed that resistance. Researchers found that a protein called TROP2 becomes elevated in these persister cells when EGFR inhibitors are used, driven by a reduction in c-Myc that normally suppresses TROP2. By combining the TROP2-targeting antibody-drug conjugate sacituzumab tirumotecan with the standard therapy osimertinib, the team was able to suppress persister cell survival and delay tumor relapse in lab models. Early data from an ongoing Phase 2 clinical trial in patients shows preliminary promise for this combination as a first-line treatment approach.
Detailed Summary
Drug resistance remains the central obstacle in treating EGFR-mutant non-small-cell lung cancer (NSCLC), which affects a significant subset of lung cancer patients, particularly in Asia. While EGFR tyrosine kinase inhibitors like osimertinib produce robust initial responses, most patients eventually relapse. Understanding why — and how to intervene earlier — is a critical clinical priority.
This study focuses on drug-tolerant persister (DTP) cells: a small subpopulation of cancer cells that survive TKI treatment in a dormant or semi-dormant state, eventually giving rise to full resistance. The researchers conducted comprehensive molecular analyses to identify what makes these cells tick and what vulnerabilities they might expose.
The key finding is that TROP2, a cell-surface protein, is dynamically upregulated during TKI-induced DTP formation. The mechanism involves the MAPK signaling pathway: when TKIs suppress MAPK activity, levels of the transcription factor c-Myc fall, and since c-Myc normally represses TROP2 expression, TROP2 rises as a result. This creates a targetable window — persister cells become dependent on TROP2 signaling at precisely the moment they are becoming drug-tolerant.
Exploiting this vulnerability, the team combined osimertinib with sacituzumab tirumotecan (sac-TMT), an antibody-drug conjugate that delivers a cytotoxic payload directly to TROP2-expressing cells. In preclinical models, this combination effectively suppressed DTP emergence and delayed tumor relapse. An ongoing Phase 2 trial is testing this combination as first-line therapy in advanced EGFR-mutant NSCLC, with preliminary efficacy signals reported.
The research is significant because it proposes a mechanism-based strategy to intercept resistance before it fully develops, rather than treating it after the fact. Caveats include the early-stage nature of the clinical data and potential conflicts of interest from industry co-authors.
Key Findings
- TROP2 is upregulated in drug-tolerant persister cells during EGFR TKI treatment, making it a actionable target.
- TKI-mediated MAPK suppression lowers c-Myc, which normally represses TROP2, explaining the mechanism of upregulation.
- Combining sacituzumab tirumotecan with osimertinib suppressed persister cell survival and delayed relapse in preclinical models.
- An ongoing Phase 2 trial shows preliminary efficacy for first-line sac-TMT plus osimertinib in EGFR-mutant NSCLC.
- TROP2-ADC plus EGFR-TKI combination may represent a first-line strategy to preempt rather than rescue TKI resistance.
Methodology
The study employed comprehensive molecular analyses to characterize TROP2 dynamics in DTP cells, including mechanistic dissection of the c-Myc/MAPK/TROP2 axis. Preclinical models were used to test the osimertinib plus sacituzumab tirumotecan combination. Clinical translation is supported by preliminary data from an ongoing Phase 2 trial, though full trial results are not yet reported.
Study Limitations
The full study details are based on the abstract only, so methodology, statistical robustness, and complete clinical data cannot be fully evaluated. The Phase 2 clinical data described as 'preliminary' requires full reporting to assess efficacy and safety. Several authors are employees of Sichuan Kelun-Biotech and Merck, representing potential conflicts of interest that warrant consideration when interpreting results.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.